The Ministry of Health and Welfare and the Korea Health Industry Development Institute (KHIDI) selected Humedix to receive government support for facilities and machines to produce a Covid-19 vaccine.

Humedix will get funding from the government to prepare equipment and facilities for producing a Russian Covid-19 vaccine.

In Huons Global’s consortium to produce Sputnik V, Humedix will mainly fill vials with vaccines and package finished products.

The consortium aims to produce 100 million doses of vaccines monthly.

To meet this goal, Humedix is pushing to expand vial lines at its second plant in Jecheon, North Chungcheong Province.

Humedix said it was picked for the government project because it received good evaluations in production facilities, manufacturing capability, the expertise of researchers, and the recruitment of new staff for vaccine manufacturing.

Humedix will receive 960 million won ($820,997) government subsidy, used for trial production and operation of added production lines.

“As we got to receive funding from the government, we will make sure to contribute to ending the Covid-19 pandemic and making Korea a global vaccine production hub,” said Kim Jin-hwan, CEO of Humedix.

The “Covid-19 Vaccine Production and Raw and Subsidiary Material Facility and Equipment Support Project,” led by the health and welfare ministry and the KHIDI, aims to support companies' production of Covid-19 vaccines and establishment of basic and subsidiary material facilities and equipment.

The support program is for companies with either facilities and technologies to produce Covid-19 vaccines on consignment or those that can prove vaccine manufacturing capabilities.

The selected company must cooperate with the government’s request for a cash investment of 100 percent or more of government subsidy and consignment manufacturing and agree that it would not use the supported facilities for purposes other than vaccine production.